DuPont de Nemours, Inc.

NOTE 19 -SEGMENT INFORMATION

The Company's segments are aligned with the market verticals they serve while maintaining integration and innovation strengths within strategic value chains. DuPont is comprised oftwo operating segments: Healthcare & Water Technologies and Diversified Industrials. Major products by segment include: Healthcare & Water Technologies (specialty components for medical devices, TYVEK® medical packaging and garments, TYCHEM® protective suits, AMBERLITE™ ion exchange resins, FILMTEC™ reverse osmosis and nanofiltration elements and INGE™ and ITEGRATEC™ ultrafiltration modules) and Diversified Industrials (TYVEK® house wrap, STYROFOAM™ insulation, CORIAN® solid surface, Vespel® shapes and parts, MOLYKOTE® specialty lubricants, BETAFORCE™ and BETASEAL™ structural adhesives and Cyrel® flexographic printing plates). The Company operates globally in substantially all of its product lines. Transfers of products between operating segments are generally valued at cost, to the extent such transfers are applicable.

The revenues and certain expenses of the Aramids Business and Electronics Business are classified as discontinued operations in the current and historical periods.

The costs of the Aramids Business and Electronics Business that are classified as discontinued operations include only direct operating expenses incurred by the businesses. Indirect costs, such as those related to corporate and shared service functions previously allocated to the Aramids Business and Electronics Business, do not meet the criteria for discontinued operations and are reported within continuing operations. A portion of these indirect costs include costs related to activities the Company has or will undertake following the closing of each of the Aramids Divestiture and Electronics Separation, and for which it has been or will be reimbursed ("Future Reimbursable Indirect Costs"). Future Reimbursable Indirect Costs are reported within continuing operations in Corporate but are excluded from Operating EBITDA (as defined below). The remaining portion of these indirect costs are not subject to future reimbursement ("Stranded Costs"). Stranded Costs are reported within continuing operations in Corporate and are included within Operating EBITDA.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM"), the Chief Executive Officer, assesses performance and allocates resources. The CODM utilizes Operating EBITDA to assess financial performance and allocate resources by comparing actual results to historical and previously forecasted results. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines ("Corporate DDOB Remediation Costs"), and is adjusted for significant items. Reconciliations of these measures are provided on the following pages.

The information below reflects segment structure as of September 30, 2026.

1. The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.

2. Other segment items include immaterial other gains or losses and miscellaneous income and expenses.

3. Depreciation is a reconciling item to Segment Operating EBITDA as it is included within "Cost of sales", "Selling, general and administrative expenses" and "Research and development expenses".

Total reportable segment net sales are $1,868 million and $1,795 million for the three months ended September 30, 2026 and 2025, respectively and $5,368 million and $5,156 million for the nine months ended September 30, 2026, and 2025, respectively.

1. Corporate includes certain enterprise and governance activities including non-allocated corporate overhead costs and support functions, leveraged services, non-business aligned litigation expenses, DuPont's equity interest in Derby and Arclin related to the Delrin® and Aramids divestitures, respectively, and other costs not absorbed by reportable segments.

2. The nine months ended September 30, 2026 and 2025 excludes accrued interest income earned on employee retention credits. The three and nine months ended September 30, 2025 excludes interest earned on cash held in escrow associated with the Qnity financing. Refer to details of significant items below.

3. The three and nine months ended September 30, 2025 excludes interest rate swap basis amortization. Refer to details of significant items below.

The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above:

2. Includes certain costs to achieve cost savings targets following the Electronics Separation and the Aramids Divestiture.

3. Includes legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($7 million pre-tax cost), offset by a benefit related to an adjustment within Healthcare & Water Technologies of the Donatelle contingent earn-out liability ($6 million pre-tax benefit).

2. Acquisition, integration and separation costs related primarily to the Electronics Separation.

3. Includes the non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. The three months ended September 30, 2025 also includes basis amortization on the 2022 Swaps ($1 million pre-tax, reflected in "Interest expense" within the interim Consolidated Statements of Operations). Refer to Note 17 for further details.

4. Reflects interest income earned on cash held in escrow related to notes transferred to Qnity upon consummation of the Qnity Distribution. See Note 3 for additional information.

5. Primarily reflects benefits related to an adjustment of the Donatelle contingent earn-out liability ($7 million pre-tax benefit), offset by legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($9 million pre-tax cost).

2. Includes certain costs to achieve cost savings targets following the Electronics Separation and the Aramids Divestiture.

3. Includes legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($10 million pre-tax cost), and legal costs associated with personal injury cases associated with Corian®Quartz, a product within the Diversified Industrials segment ($18 million pre-tax cost), offset by a benefit related to an adjustment within Healthcare & Water Technologies of the Donatelle contingent earn-out liability ($20 million pre-tax benefit) and accrued interest earned on employee retention credits ($3 million pre-tax benefit).

2. Acquisition, integration and separation costs related primarily to the Electronics Separation.

3. Includes the non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. The nine months ended September 30, 2025 also includes basis amortization on the 2022 Swaps ($2 million pre-tax, reflected in "Interest expense" within the interim Consolidated Statements of Operations). Refer to Note 17 for further details.

4. Reflects interest income earned on cash held in escrow related to notes transferred to Qnity upon consummation of the Qnity Distribution. See Note 3 for additional information.

5. Primarily reflects benefits related to an adjustment of the Donatelle contingent earn-out liability ($19 million pre-tax benefit) and accrued interest earned on employee retention credits ($6 million pre-tax benefit), offset by legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($14 million pre-tax cost).

1. Reflects the incremental cash spent or unpaid on capital expenditures; total capital expenditures are presented on a cash basis.